Rhumbline Advisers trimmed its holdings in BioAtla, Inc. (NASDAQ:BCAB – Free Report) by 67.9% in the course of the 2nd quarter, in response to the corporate in its most up-to-date Kind 13F submitting with the SEC. The fund owned 20,151 shares of the corporate’s inventory after promoting 42,644 shares in the course of the quarter. Rhumbline Advisers’ holdings in BioAtla have been value $28,000 on the finish of the latest reporting interval.
A number of different hedge funds additionally just lately added to or lowered their stakes within the enterprise. Valmark Advisers Inc. acquired a brand new place in shares of BioAtla within the 2nd quarter valued at about $34,000. Rinkey Investments bought a brand new place in BioAtla in the course of the second quarter valued at roughly $35,000. Value T Rowe Associates Inc. MD bought a brand new place in BioAtla in the course of the first quarter valued at roughly $45,000. Virtu Monetary LLC acquired a brand new place in BioAtla within the first quarter valued at roughly $103,000. Lastly, Pale Hearth Capital SE boosted its place in BioAtla by 204.6% within the 4th quarter. Pale Hearth Capital SE now owns 48,383 shares of the corporate’s inventory value $119,000 after buying a further 32,500 shares within the final quarter. 77.23% of the inventory is owned by hedge funds and different institutional buyers.
Wall Road Analysts Forecast Progress
Individually, JMP Securities reaffirmed a “market outperform” score and set a $5.00 goal value on shares of BioAtla in a report on Monday, September sixteenth.
Get Our Newest Evaluation on BCAB
BioAtla Inventory Efficiency
Shares of BioAtla inventory opened at $1.73 on Wednesday. The agency has a 50-day easy transferring common of $1.71 and a two-hundred day easy transferring common of $2.06. BioAtla, Inc. has a fifty-two week low of $1.14 and a fifty-two week excessive of $4.02. The corporate has a market cap of $83.24 million, a P/E ratio of -0.69 and a beta of 1.06.
BioAtla (NASDAQ:BCAB – Get Free Report) final launched its quarterly earnings outcomes on Thursday, August eighth. The corporate reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01. Throughout the identical interval final yr, the agency posted ($0.75) earnings per share. Equities analysis analysts forecast that BioAtla, Inc. will publish -1.52 EPS for the present yr.
BioAtla Profile
BioAtla, Inc, a clinical-stage biopharmaceutical firm, develops particular and selective antibody-based therapeutics for the remedy of strong tumor most cancers. The corporate’s lead medical stage product candidates embody mecbotamab vedotin (BA3011), a conditionally energetic biologic (CAB) antibody-drug conjugate (ADC), which is in Section II medical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung most cancers (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that’s in Section II medical trial for the remedy of melanoma and squamous cell most cancers of the top and neck.
See Additionally
Wish to see what different hedge funds are holding BCAB? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for BioAtla, Inc. (NASDAQ:BCAB – Free Report).
Obtain Information & Rankings for BioAtla Each day – Enter your e-mail tackle beneath to obtain a concise each day abstract of the most recent information and analysts’ scores for BioAtla and associated corporations with MarketBeat.com’s FREE each day e-mail publication.
